-
Item confirms peer-reviewed
A claims-wide screen of SGLT2 inhibitors in kidney disease finds no new harms
A scan of all diagnosis codes in 31,246 matched pairs of US patients with type 2 diabetes and stage III to IV chronic kidney disease found only the already-known genital infection signal for SGLT2 inhibitors against GLP-1 receptor agonists, with nothing from inpatient or emergency codes.
-
Item confirms peer-reviewed
Cost-effectiveness of antiobesity drugs varies widely across 26 published models
A systematic review of 26 full economic evaluations of approved antiobesity medications found the results heterogeneous and highly sensitive to model assumptions, with semaglutide consistently more cost-effective than liraglutide and tirzepatide often above lower willingness-to-pay thresholds.
-
Item new preprint
Peer-derived fMRI neurofeedback during a film reduced craving in opioid use disorder
A real-time fMRI study trained people with opioid use disorder to align prefrontal activity with a signal derived from peers further into recovery watching the same film, and reported reduced craving against sham feedback, in a preprint that gives no sample size.
-
Item refines peer-reviewed
Bempedoic acid cut LDL-C 17.5% in routine use and a quarter stopped within three months
In 641 patients at seven German lipid clinics, adding bempedoic acid lowered LDL-C by a mean 17.5% at three months, though 34.0% had a suspected adverse event and 26.7% had stopped the drug by follow-up.
-
Item new preprint
Daraxonrasib is estimated at $500,637 per QALY in pancreatic cancer at US launch price
A modelled economic evaluation of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma estimated 0.506 additional QALYs at an incremental cost of $253,171, or $500,637 per QALY at the $39,800 monthly launch price, in a preprint not yet peer reviewed.
-
Item refines preprint
Self-guided lipid app cut LDL-cholesterol by 3.9% more than usual care over six months
In a pragmatic online trial of 278 adults with LDL-cholesterol above their risk-adapted target, a fully self-guided lifestyle app added to usual care reduced LDL by 3.9% more than usual care alone at six months, with 41.7% versus 23.8% achieving a fall of at least 10%.
-
Item new peer-reviewed
An oral KRAS G12D inhibitor shrank tumours in a third of treated pancreatic cancers
In a phase 1 trial of 74 heavily pretreated patients with KRAS G12D-mutant advanced solid tumours, the oral inhibitor GFH375 produced confirmed responses in 35.1% of pancreatic cancers and 35.7% of non-small cell lung cancers, with median overall survival of 9.9 and 13.4 months respectively.
